1、單選題血清中半衰期最長(zhǎng)的抗體是A: <span>IgE類抗體</span>B: <span>IgM類抗體</span>C: <span>IgA類抗體</span>D: <span>IgG類抗體</span>E: <span>IgD類抗體</span>單選題人類的中樞免疫器官包括A: <span>扁桃體和闌尾</span>B: <span>骨髓和腔上囊</span>C: <span>骨髓和胸腺</span>

2、D: <span>脾和淋巴結(jié)</span>E: <span>腸相關(guān)淋巴組織</span>單選題ABO血型的天然抗體是A: <span>IgA類抗體 </span>B: <span>IgM類抗體</span>C: <span>IgG類抗體</span>D: <span>IgD類抗體 </span>E: <span>IgE類抗體 </span&

3、gt;單選題分離外周血單個(gè)核細(xì)胞常用的方法是A: <span>流式細(xì)胞術(shù)分選法</span>B: <span>免疫吸附分離法</span>C: <span>免疫磁珠分離法</span>D: <span>酶聯(lián)免疫吸附試驗(yàn)</span>E: <span>葡聚糖-泛影葡胺密度梯度離心法</span>單選題內(nèi)源性抗原在抗原提呈細(xì)胞內(nèi)消化降解的部位A: <span>蛋白酶體 </span>B: <span>內(nèi)體/溶酶體 </span>C:

4、 <span>內(nèi)質(zhì)網(wǎng) </span>D: <span>MHC類器室 </span>E: <span>溶酶體</span>單選題抗原分子中的構(gòu)象表位A: <span>多位于抗原分子內(nèi)部</span>B: <span>是隱蔽性抗原表位</span>C: <span>是T細(xì)胞主要識(shí)別的表位</span>D: <span>是B細(xì)胞主要識(shí)別的表位</span>E: <span>是被抗原提呈細(xì)胞加工后形成的抗原表位</sp

5、an>單選題脾小結(jié)生發(fā)中心內(nèi)聚集的免疫細(xì)胞主要是A: <span>增殖分化的B細(xì)胞</span>B: <span>并指樹(shù)突狀細(xì)胞</span>C: <span>增殖分化的Th1細(xì)胞</span>D: <span>巨噬細(xì)胞</span>E: <span>增殖分化的CTL細(xì)胞</span>單選題免疫原性是指A: <span>抗原刺激機(jī)體產(chǎn)生免疫應(yīng)答的能力</span>B: <span>抗原與相應(yīng)免疫應(yīng)答產(chǎn)物特異性結(jié)合的能力</spa

6、n>C: <span>抗原與大分子載體結(jié)合的能力</span>D: <span>抗原與相應(yīng)效應(yīng)T細(xì)胞特異性結(jié)合的能力</span>E: <span>抗原與相應(yīng)抗體特異性結(jié)合的能力</span>單選題具有抗原加工提呈作用的專職APC是A: <span>內(nèi)皮細(xì)胞</span>B: <span>成纖維細(xì)胞</span>C: <span>病毒感染細(xì)胞</span>D: <span>樹(shù)突狀細(xì)胞</span>E: <span&g

7、t;腫瘤細(xì)胞</span>單選題大多數(shù)抗原抗體反應(yīng)的最適溫度為A: <span>56</span>B: <span>37</span>C: <span>25</span>D: <span>20</span>E: <span>4</span>單選題分子量最大的免疫球蛋白是A: <span>IgG</span>B: <span> IgM </span>C: <span> IgA</span>D:

8、<span> IgD </span>E: <span> IgE</span>單選題能夠通過(guò)胎盤進(jìn)入胎兒體內(nèi)的抗體是A: <span>IgA類抗體</span>B: <span>SIgA類抗體</span>C: <span>IgE類抗體</span>D: <span>IgG類抗體</span>E: <span>IgM類抗體</span>單選題抑制B細(xì)胞產(chǎn)生IgE抗體的細(xì)胞因子是A: <span>IL-2 </sp

9、an>B: <span>IL-3</span>C: <span>IL-4 </span>D: <span>TNF-</span>E: <span>IFN-</span>單選題患者多次輸血后發(fā)生非溶血性輸血反應(yīng)的原因是A: <span>患者體內(nèi)產(chǎn)生了抗自身HLA-I類抗原的特異性抗體</span>B: <span>患者體內(nèi)產(chǎn)生了抗供者HLA-I類抗原的特異性抗體</span>C: <span>患者體內(nèi)產(chǎn)生了抗自身HLA-II類抗原的特異

10、性抗體</span>D: <span>患者與供者ABO血型不符</span>E: <span>患者與供者Rh抗原不符</span>單選題具有免疫粘附作用的補(bǔ)體裂解片段是A: <span>C3b和C4b</span>B: <span>C3b和C5b</span>C: <span>C4b和C5b</span>D: <span>C2b和C3b</span>E: <span>C2b和C5b</span>單選題屬于I型超敏反應(yīng)

11、的疾病是A: <span>過(guò)敏性鼻炎t</span>B: <span>接觸性皮炎t</span>C: <span>類Arthus反應(yīng)t</span>D: <span>新生兒溶血癥t</span>E: <span>重癥肌無(wú)力</span>單選題屬于人工被動(dòng)免疫的措施是A: <span>注射抗毒素獲得的免疫 </span>B: <span>通過(guò)胎盤或初乳獲得的免疫</span>C: <span>注射類毒素獲得的免疫 &l

12、t;/span>D: <span>傳染病痊愈后獲得的免疫 </span>E: <span>注射疫苗獲得的免疫</span>單選題檢測(cè)可溶性抗原不能采用A: <span>免疫印跡法</span>B: <span>免疫比濁發(fā)</span>C: <span>單向瓊脂擴(kuò)散</span>D: <span>直接凝聚反應(yīng)</span>E: <span>間接凝聚反應(yīng)</span>單選題CTL殺傷靶細(xì)胞的特點(diǎn)A: <span>無(wú)

13、需細(xì)胞直接接觸 </span>B: <span>作用無(wú)特異性 </span>C: <span>不需細(xì)胞因子參與 </span>D: <span>不需要抗原刺激 </span>E: <span>釋放穿孔素、顆粒酶和表達(dá)FasL</span>單選題B細(xì)胞接受TI抗原刺激后，產(chǎn)生的抗體主要是A: <span>高親和力IgM類抗體 </span>B: <span>低親和力IgM類抗體 </span>C: <span>高親和力IgG類抗體

14、 </span>D: <span>低親和力IgG類抗體 </span>E: <span>低親和力IgE類抗體</span>單選題選擇性刺激造血干細(xì)胞增殖分化的細(xì)胞因子是：A: <span>IL </span>B: <span>TNF </span>C: <span>IFN </span>D: <span>CSF </span>E: <span>TGF </span>單選題表達(dá)于APC表面可誘導(dǎo)CTL細(xì)胞產(chǎn)生活化第一信

15、號(hào)的物質(zhì)是A: <span> B7-1/2分子</span>B: <span> 抗原肽-MHC-類分子復(fù)合物</span>C: <span> ICAM-1分子</span>D: <span> 抗原肽-MHC-類分子復(fù)合物</span>E: <span> 脂類抗原-CD1分子復(fù)合物</span>單選題可通過(guò)合成分泌TGF-和（或）IL-10發(fā)揮免疫抑制作用的T細(xì)胞是A: <span>Th17細(xì)胞t</span>B: <span>Th2細(xì)胞t&

16、lt;/span>C: <span>Treg細(xì)胞t</span>D: <span>Th1細(xì)胞t</span>E: <span>T細(xì)胞t</span>單選題慢性寄生蟲(chóng)感染時(shí)機(jī)體內(nèi)哪類免疫球蛋白顯著升高A: <span>IgG</span>B: <span> IgM </span>C: <span> IgA</span>D: <span> IgD </span>E: <span> IgE</span>單

17、選題下列物質(zhì)中免疫原性最強(qiáng)的是A: <span>脂多糖</span>B: <span>脂蛋白</span>C: <span>多糖</span>D: <span>核酸</span>E: <span>蛋白質(zhì)</span>單選題血清中半衰期最長(zhǎng)的抗體是A: <span>IgE類抗體</span>B: <span>IgM類抗體</span>C: <span>IgA類抗體</span>D: <span>

18、IgG類抗體</span>E: <span>IgD類抗體</span>單選題人類的中樞免疫器官包括A: <span>扁桃體和闌尾</span>B: <span>骨髓和腔上囊</span>C: <span>骨髓和胸腺</span>D: <span>脾和淋巴結(jié)</span>E: <span>腸相關(guān)淋巴組織</span>單選題ABO血型的天然抗體是A: <span>IgA類抗體 </span>B: <span>

19、IgM類抗體</span>C: <span>IgG類抗體</span>D: <span>IgD類抗體 </span>E: <span>IgE類抗體 </span>單選題分離外周血單個(gè)核細(xì)胞常用的方法是A: <span>流式細(xì)胞術(shù)分選法</span>B: <span>免疫吸附分離法</span>C: <span>免疫磁珠分離法</span>D: &

20、lt;span>酶聯(lián)免疫吸附試驗(yàn)</span>E: <span>葡聚糖-泛影葡胺密度梯度離心法</span>單選題內(nèi)源性抗原在抗原提呈細(xì)胞內(nèi)消化降解的部位A: <span>蛋白酶體 </span>B: <span>內(nèi)體/溶酶體 </span>C: <span>內(nèi)質(zhì)網(wǎng) </span>D: <span>MHC類器室 </span>E: <span>溶酶體</span>單選題抗原分子中的構(gòu)象表位A: <span>多位于抗原分子內(nèi)

21、部</span>B: <span>是隱蔽性抗原表位</span>C: <span>是T細(xì)胞主要識(shí)別的表位</span>D: <span>是B細(xì)胞主要識(shí)別的表位</span>E: <span>是被抗原提呈細(xì)胞加工后形成的抗原表位</span>單選題脾小結(jié)生發(fā)中心內(nèi)聚集的免疫細(xì)胞主要是A: <span>增殖分化的B細(xì)胞</span>B: <span>并指樹(shù)突狀細(xì)胞</span>C: <span>增殖分化的Th1細(xì)胞</span

22、>D: <span>巨噬細(xì)胞</span>E: <span>增殖分化的CTL細(xì)胞</span>單選題免疫原性是指A: <span>抗原刺激機(jī)體產(chǎn)生免疫應(yīng)答的能力</span>B: <span>抗原與相應(yīng)免疫應(yīng)答產(chǎn)物特異性結(jié)合的能力</span>C: <span>抗原與大分子載體結(jié)合的能力</span>D: <span>抗原與相應(yīng)效應(yīng)T細(xì)胞特異性結(jié)合的能力</span>E: <span>抗原與相應(yīng)抗體特異性結(jié)合的能力</span&

23、gt;單選題具有抗原加工提呈作用的專職APC是A: <span>內(nèi)皮細(xì)胞</span>B: <span>成纖維細(xì)胞</span>C: <span>病毒感染細(xì)胞</span>D: <span>樹(shù)突狀細(xì)胞</span>E: <span>腫瘤細(xì)胞</span>單選題大多數(shù)抗原抗體反應(yīng)的最適溫度為A: <span>56</span>B: <span>37</span>C: <span>25</span>D: &l

24、t;span>20</span>E: <span>4</span>單選題分子量最大的免疫球蛋白是A: <span>IgG</span>B: <span> IgM </span>C: <span> IgA</span>D: <span> IgD </span>E: <span> IgE</span>單選題能夠通過(guò)胎盤進(jìn)入胎兒體內(nèi)的抗體是A: <span>IgA類抗體</span>B: <span>SI

25、gA類抗體</span>C: <span>IgE類抗體</span>D: <span>IgG類抗體</span>E: <span>IgM類抗體</span>單選題抑制B細(xì)胞產(chǎn)生IgE抗體的細(xì)胞因子是A: <span>IL-2 </span>B: <span>IL-3</span>C: <span>IL-4 </span>D: <span>TNF-</span>E: <span>IFN-</span&

26、gt;單選題患者多次輸血后發(fā)生非溶血性輸血反應(yīng)的原因是A: <span>患者體內(nèi)產(chǎn)生了抗自身HLA-I類抗原的特異性抗體</span>B: <span>患者體內(nèi)產(chǎn)生了抗供者HLA-I類抗原的特異性抗體</span>C: <span>患者體內(nèi)產(chǎn)生了抗自身HLA-II類抗原的特異性抗體</span>D: <span>患者與供者ABO血型不符</span>E: <span>患者與供者Rh抗原不符</span>單選題具有免疫粘附作用的補(bǔ)體裂解片段是A: <span>C3b

27、和C4b</span>B: <span>C3b和C5b</span>C: <span>C4b和C5b</span>D: <span>C2b和C3b</span>E: <span>C2b和C5b</span>單選題屬于I型超敏反應(yīng)的疾病是A: <span>過(guò)敏性鼻炎t</span>B: <span>接觸性皮炎t</span>C: <span>類Arthus反應(yīng)t</span>D: <span>新生兒溶血癥t

28、</span>E: <span>重癥肌無(wú)力</span>單選題屬于人工被動(dòng)免疫的措施是A: <span>注射抗毒素獲得的免疫 </span>B: <span>通過(guò)胎盤或初乳獲得的免疫</span>C: <span>注射類毒素獲得的免疫 </span>D: <span>傳染病痊愈后獲得的免疫 </span>E: <span>注射疫苗獲得的免疫</span>單選題檢測(cè)可溶性抗原不能采用A: <span>免疫印跡法</span&

29、gt;B: <span>免疫比濁發(fā)</span>C: <span>單向瓊脂擴(kuò)散</span>D: <span>直接凝聚反應(yīng)</span>E: <span>間接凝聚反應(yīng)</span>單選題CTL殺傷靶細(xì)胞的特點(diǎn)A: <span>無(wú)需細(xì)胞直接接觸 </span>B: <span>作用無(wú)特異性 </span>C: <span>不需細(xì)胞因子參與 </span>D: <span>不需要抗原刺激 </span>E: <span>釋放穿孔素、顆粒酶和表達(dá)FasL</span>單選題B細(xì)胞接受TI抗原刺激后，產(chǎn)生的抗體主要是A: <span>高親和力IgM類抗體 </span>B: <span>低親和力IgM類抗體 </span>C: <span>高親和力IgG類抗體 </span>D: <span>低親和力IgG類抗體 </span>E: <span>低親和力IgE